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 Abstract 
 Background: Disturbances in the levels of one-carbon (1C) 
metabolism metabolites have been associated with a wide 
variety of neuropsychiatric diseases. Cerebrospinal fl uid 
(CSF) levels of homocysteine (Hcy) and the other 1C metab-
olites, nor their interrelatedness and putative determinants, 
have been studied extensively in a healthy population. 
 Methods: Plasma and CSF samples from 100 individu-
als free from neuropsychiatric diseases were analyzed (55 
male, 45 female; age 50 ± 17 years). In blood, we measured 
plasma Hcy, serum folate and serum vitamin B12. In CSF, 
we measured total Hcy, S-adenosylmethionine (SAM), 
S-adenosylhomocysteine (SAH) and 5-methyltetrahydrofo-
late (5-methylTHF). Highly selective analytical methods like 
liquid chromatography combined with either mass spectrom-
etry or fl uorescence detection were used. 
 Results: CSF Hcy was inversely correlated with CSF 
5-methylTHF and positively with plasma Hcy, independent 
of serum folate status. CSF SAH correlated with age, lower 
CSF 5-methylTHF and higher CSF Hcy. CSF 5-methylTHF 
showed independent negative correlations with age and 
positive correlations with serum folate. CSF SAM did not 
correlate with any of the 1C metabolites. 
 Conclusions: Aging is characterized by a reduction in CSF 
5-methylTHF levels and increased CSF levels of the poten-
tially neurotoxic transmethylation inhibitor SAH. CSF 
5-methylTHF, which is itself determined in part by systemic 
folate status, is a powerful independent determinant of CSF 
levels of Hcy and SAH. 
 Keywords:  cerebrospinal fl uid;  folate;  homocysteine; 
 S-adenosylhomocysteine;  S-adenosylmethionine. 
 Introduction 
 One-carbon (1C) metabolism encompasses a series of bio-
chemical reactions that involves the transfer of 1C moieties 
(Figure  1 ). One of its main purposes is to provide methyl 
groups for virtually all transmethylation reactions. One car-
bon metabolism has been the focus of extensive research, 
particularly since increased plasma levels of one of its inter-
mediates, homocysteine (Hcy), were linked to numerous 
diseases, such as cardiovascular disease  (3) and neurological 
disease  (4, 5) . 
 Studies with small sample sizes have also shown correla-
tions of these neurological diseases with Hcy in cerebrospinal 
fl uid (CSF)  (6, 7) . To date, however, several uncertainties sur-
round the association between increased plasma levels of Hcy 
and neuropsychiatric disease. Firstly, it is unclear whether 
plasma or CSF concentrations of these constituents are pri-
marily of interest. In addition, it remains unclear whether 
Hcy itself or one of the other constituents of 1C metabolism 
exerts detrimental effects on the neural system. Potential can-
didates in this context include S-adenosylmethionine (SAM), 
S-adenosylhomocysteine (SAH) and B-vitamin status. 
 SAM is the methyl donor in many essential methylation 
reactions, such as DNA methylation, synthesis and inacti-
vation of neurotransmitters, and myelin synthesis. SAH has 
opposite effects, in that it acts as a powerful inhibitor of most 
transmethylation reactions  (8) . The SAM/SAH ratio has been 
used as a refl ection of methylation potential in, amongst oth-
ers, the central nervous system (CNS)  (9) . The potential rel-
evance of SAM is supported by observations that low SAM 
levels in CSF are associated with depression and dementia 
 (10) . The effect of SAH on neuropsychiatric disturbances is 
less well studied. However, the CSF levels of SAH are asso-
ciated with CSF levels of hyperphosphorylated tau, a marker 
for Alzheimer pathology  (11) . 
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 One-carbon metabolism is critically dependent on the 
B-vitamin status (B2, B6, B12 and, predominantly, folate) 
 (12) . Defi ciencies of B-vitamins are commonly seen in the 
elderly population  (13, 14) . As the remethylation pathway 
via betaine is not expressed in the brain, the only option for 
remethylation of Hcy, and thus regeneration of methionine, 
is via 5-methyltetrahydrofolate (5-methylTHF, Figure 1). 
Therefore, low 5-methylTHF levels could not only increase 
Hcy levels but could also potentially diminish the methy-
lation capacity of the brain  (15) . Additionally, folates are 
involved in DNA synthesis; also low folate levels could 
potentially impair DNA stability and structure, for example 
by the misincorporation of uracil in DNA  (16) . The literature 
on folate status as an independent risk factor for neuropsy-
chiatric diseases indicates that low levels of 5-methylTHF in 
CSF are found in patients suffering from a wide spectrum of 
neuropsychiatric diseases, such as Alzheimer, depression and 
autism  (17 – 20) . Additionally, the absence of 5-methylTHF in 
CSF in rare inborn errors of metabolism causes progressive 
neurological decline  (21) . 
 In short, concentrations in the CNS of Hcy, but also of other 
1C metabolites, in particular SAM, SAH and 5-methylTHF, 
may be of relevance for the development of neuropsychiatric 
diseases. A better understanding of the determinants of these 
intermediates is important. This paper focuses on identifi ca-
tion of determinants of Hcy, SAM, SAH and 5-methylTHF 
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 Figure 1  Overview of the 1 carbon metabolic pathway in humans. 
Homocysteine (Hcy) can follow two pathways. 
 It could be remethylated to methionine and subsequently converted to 
the universal methyl donor S-adenosylmethionine (SAM). Disturbed 
remethylation infl uences methylation reactions, such as the methy-
lation of neurotransmitters or DNA. Alternatively, Hcy can be irre-
versibly converted to cystathionine and further to cysteine. However, 
whether this transsulfuration pathway is active in the brain, is still 
debated  (1) . Elevated Hcy levels could also infl uence SAH levels by 
the equilibrium reaction. High SAH is an inhibitor of a wide variety 
of methyltransferases  (2) . MS, methionine synthase; MTHFR, methy-
lene tetrahydrofolate reductase; CBS, cystathionine  β -synthase; MAT, 
methionine adenosyl transferase; SH, SAH hydrolase. 
in CSF of individuals unaffected by neuropsychiatric disease. 
Additionally, the reference values in this paper will offer an 
indication for the sample size estimation of future studies. 
 Materials and methods 
 Subjects 
 Ninety-eight subjects, who were subjected to a lumbar puncture (for 
different indications, such as exclusion of CNS infl ammation, exclu-
sion of aneurysmal subarachnoid hemorrhage or exclusion of men-
ingitis, all negative) at the Department of Neurology (University of 
Bonn), were enrolled in this study. Except for the symptoms they 
presented with, majorly acute, but not chronic cepahlgia, none of the 
enrolled subjects showed evidence or history of cognitive impair-
ment or any other symptoms of possible neurological or psychiatric 
disease; which were exclusion criteria. Additional exclusion cri-
teria for this study were: chronic or unstable medical illness (e.g., 
symptomatic cardiac disease, renal or hepatic dysfunction, insulin-
dependent diabetes mellitus, untreated thyroidal dysfunction), ex-
cessive alcohol intake, vitamin supplementation, disturbance of the 
blood brain-barrier (defi ned as CSF whole protein content  > 500mg/
dL), or infl ammation of the central nervous system (i.e., more than 5 
leucocytes/mm 3 or intrathecal immunglobulin production) or an ab-
normal result in the Mini Mental State Examination (MMSE), which 
was done for all subjects  (22) . The study was approved by the Local 
Ethics Committee, written informed consent was obtained from all 
study participants. 
 Sample collection 
 Diagnostic lumbar punctures were performed at the Department of 
Neurology, University of Bonn. A standardized technique with a 20G 
 “ atraumatical ” spinal needle and a sitting or lying position for the 
patient was applied. Approximately 10 – 14 mL of CSF was removed 
for analysis. Depending on the indication of the lumbar puncture, 
the fi rst fractions were used for diagnostic purposes, the third or 
fourth for the current study. CSF samples were frozen immediately 
on dry ice. 
 Fasting venous blood was collected in lithium heparin vacutainers 
and immediately placed on ice. Plasma was isolated by centrifuga-
tion for 10 min at 2000  g at 4 ° C. Light protected sera were used for 
the folate and vitamin B12 measurements; these were centrifuged for 
10 min at 3300  g at room temperature. All samples were stored at 
 – 80 ° C until analysis. 
 Methods 
 Plasma total Hcy concentrations were determined by means 
of fully automated particle-enhanced immunonephelo metry 
with a BN II System (Siemens Healthcare Diagnostics 
GmbH, Eschborn, Germany). The intraassay and interassay 
coeffi cient of variation (CV) of the homocysteine assay were 
3.4 % and 5.6 % , respectively. 
 Serum vitamin B12 and folate concentrations were deter-
mined by means of a competitive chemiluminescent immu-
noassay with an Access ™ Immunoassay System (Beckman 
Coulter, Krefeld, Germany). The intraassay and inter-
assay CVs of the vitamin B12 assay were 3.8 % and 6.3 % , 
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respectively. The intraassay and interassay CVs of the folate 
assay were 2.8 % and 4.8 % , respectively. 
 CSF SAM and SAH concentrations were determined by 
liquid chromatography - tandem mass spectrometry (LC-MS/
MS) (API3000, Applied Biosystems, Foster City, CA, USA). 
The intraassay and interassay CVs for SAM were 6.8 % and 
4.2 % , respectively. The intraassay and interassay CVs for 
SAH were 6.9 % and 5.5 % , respectively  (23) . 
 CSF folate vitamers were determined by LC-MS/MS 
(API3000, Applied Biosystems). Intraassay and interassay 
CVs for 5-methylTHF were 1.2 % and 2.8 % , respectively. 
Intraassay and interassay CVs for non-methylTHF as a group 
were 1.6 % and 1.5 % , respectively  (24) . 
 CSF total Hcy concentrations were measured by HPLC 
using fl uorescence detection (Waters, Milford, MA, USA). An 
adaptation of a previously published method was used  (25) . 
In order to be able to measure the nanomolar homocysteine 
concentration in 100  μ L of CSF accurately, the reaction 
volume was minimized and a fl ushing gradient (30 % ace-
tonitrile) was added after each injection to create a more sta-
ble HPLC baseline. The intraassay and interassay CVs were 
2.2 % and 3.6 % , respectively. 
 Statistical analysis 
 All statistical analyses were performed using SPSS 17.0 for 
Windows. Most of the measured parameters showed posi-
tively skewed distributions (plasma Hcy, CSF Hcy, serum 
folate, serum B12, CSF SAH, CSF SAM/SAH), so the data 
were log transformed prior to regression analysis. As outlined 
in the Introduction, the main dependent variables of interest 
in CSF were Hcy, SAM, SAH, SAM/SAH and 5-methylTHF. 
We performed separate analyses to identify determinants of 
these CSF constituents. 
 In order to reduce the risk of fi nding associations by chance, 
a priori hypotheses regarding plausible determinants of the 
dependent variables of interest were formulated using avail-
able knowledge of 1C metabolism and epidemiology. For 
CSF Hcy, we fi rst assessed traditional determinants known 
to infl uence plasma Hcy, namely age and B-vitamin status (in 
both plasma and CSF). In order to determine whether serum 
folate status would determine CSF Hcy via its correlation 
with CSF folate status, serum folate and CSF 5-methylTHF 
were analyzed in a multiple regression model. In addition, we 
analyzed the correlation between plasma vs. CSF Hcy, and 
adjusted associations between serum folate status and CSF 
Hcy for plasma Hcy. All signifi cant determinants of CSF Hcy 
were fi nally entered into a single multiple regression model. 
 For CSF SAM, SAH and their ratio, the following poten-
tial determinants were analyzed: age, serum B vitamin status, 
plasma and CSF Hcy and CSF 5-methylTHF. Positive corre-
lations were analyzed for independence, again with multiple 
regression analysis 
 Finally, for CSF 5-methylTHF, we assessed whether its 
concentration independently correlated with age and/or serum 
folate status and whether the CSF 5-methylTHF/serum folate 
ratio correlated with age. 
 Table 1  Study population characteristics. 
Age, years   50 ± 17
Gender, male/female, n   55/45
Plasma homocysteine,  μ M   11 (4 – 34)
Serum total folate, nmol/L   11 (2 – 39)
Serum vitamin B12, pg/mL 325 ± 126
CSF homocysteine, nmol/L   61 (13 – 303)
CSF 5-methylTHF, nmol/L   42 ± 14
CSF non-methylTHF, nmol/L   0 (0 – 12)
Non-methylTHF,  %   0 (0 – 31)
CSF SAM, nmol/L 205 ± 41
CSF SAH, nmol/L   22 (11 – 49)
CSF SAM/SAH   9 (3 – 20)
 Data are presented as mean (SD) or, in case of skewed distributions, 
as median (range). 
 As most of the measured parameters were log transformed, 
interpretation of the effect size of a given determinant on the 
investigated 1C metabolite is diffi cult. In order to display 
the effect sizes more clearly, we divided the non-logarithmic 
transformed levels of the investigated metabolites into tertiles, 
repeated the multivariate analyses and plotted the increase in the 
dependent variable in tertiles, with the fi rst tertile as reference. 
 Results 
 Characteristics of included individuals are listed in Table  1 . 
CSF values for Hcy, folate, SAM, and SAH compared well 
with a previous reported study  (9) . Some individuals showed 
hyperhomocysteinemia in plasma, which coincided with low 
serum folate levels. Subjects were not excluded for this rea-
son. With regard to the comparison of 1C metabolites levels 
in CSF to plasma, CSF Hcy levels were a 100-fold lower than 
the plasma levels. Remarkably, CSF folate levels were sub-
stantially higher than plasma levels. SAM and SAH levels in 
CSF were comparable to plasma levels, previously determined 
 Table 2  Univariate and multivariate regression models of 
determinants of CSF Hcy. 
Regression 
type
Dependent Independent  β p-Value
Univariate CSF Hcy c Age   0.181 0.075
Univariate CSF Hcy c CSF 5-methylTHF  – 0.495 0.000 b 
Univariate CSF Hcy c Plasma Hcy c   0.331 0.001 b 
Univariate CSF Hcy c Serum folate c  – 0.244 0.019 a 
Univariate CSF Hcy c Serum B12 c  – 0.176 0.094
Univariate CSF Hcy c CSF SAH c   0.380 0.000 b 
Multivariate 1 CSF Hcy c CSF 5-methylTHF  – 0.499 0.000 b 
Serum folate c   0.008 0.943
Multivariate 2 CSF Hcy c Plasma Hcy c   0.279 0.016 a 
Serum folate c  – 0.109 0.339
Multivariate 3 CSF Hcy c CSF 5-methylTHF  – 0.338 0.001 b 
Plasma Hcy c   0.204 0.027 a 
CSF SAH c   0.265 0.004 b 
 
a
 Correlation is signifi cant at the 0.05 level (2-tailed),  b correlation is 
signifi cant at the 0.01 level (2-tailed),  c log transformed data. 
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using similar analytical methods  (26) . Of note, folate existed 
in CSF predominantly in the 5-methylTHF form, as was pre-
viously described for plasma  (27) . With regard to gender, no 
signifi cant correlations with any of the parameters were found 
(data not shown). 
 Determinants of CSF Hcy 
 For the potential determinants of CSF Hcy listed in the 
Methods section, the univariate correlations were deter-
mined. The results are listed in Table  2 . CSF Hcy levels were 
positively correlated with plasma Hcy and CSF SAH, then 
negatively correlated with serum folate and CSF folate. Age, 
a traditional determinant of plasma Hcy, just failed to reach 
signifi cance for CSF Hcy (p = 0.075). 
 Multiple regression analysis was used to determine inter-
dependence of the univariate correlations. As is evident from 
both multivariate regression model 1 and 2 in Table 2, serum 
folate is not an independent determinant of CSF Hcy. Rather, 
its correlation with CSF Hcy is predominantly explained by 
its effect on CSF 5-methylTHF and plasma Hcy. 
 As explained in Figure 1, the metabolic fate of Hcy is 
determined by several pathways, implying that its concentra-
tion could be independently correlated to parameters related 
to these pathways. Regression model 3 indeed identifi ed CSF 
5-methylTHF (remethylation), plasma Hcy (import/export 
across the blood-brain barrier) and CSF SAH (SAH hydro-
lase activity) as independent determinants of CSF Hcy levels. 
When age and vitamin B12 were forced into the multiple 
regression model, they were again not signifi cantly related to 
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 Figure 2  Change in CSF Hcy, CSF folate and CSF SAH, in respective tertiles (multivariate regression model). 
 Effect sizes were adjusted for the variables as indicated in Table 2. 
Brought to you by | Vrije Universiteit Amsterdam
Authenticated | 130.37.129.78
Download Date | 10/30/13 11:13 AM
Smith et al.: Determinants of one-carbon metabolites in cerebrospinal fl uid  1645
 Table 3  Univariate and multivariate regression models of determinants of CSF SAM, SAH and SAM/SAH. 
Regression 
type
Dependent Independent  β p-Value
Univariate CSF SAM Age   0.033 0.750
Univariate CSF SAM CSF 5-methylTHF   0.093 0.365
Univariate CSF SAM CSF Hcy c   0.164 0.107
Univariate CSF SAH c Age   0.462 0.000 b 
Univariate CSF SAH c CSF 5-methylTHF  – 0.321 0.001 b 
Univariate CSF SAH c CSF Hcy c   0.380 0.000 b 
Univariate CSF SAM/SAH c Age  – 0.405 0.000 b 
Univariate CSF SAM/SAH c CSF 5-methylTHF   0.361 0.000 b 
Univariate CSF SAM/SAH c CSF Hcy c  – 0.252 0.012 a 
Multivariate CSF SAH Age   0.391 0.000 b 
CSF 5-methylTHF  – 0.097 0.336
CSF Hcy c   0.261 0.010 a 
Multivariate CSF SAM/SAH Age  – 0.333 0.001 b 
CSF 5-methylTHF   0.246 0.022 a 
CSF Hcy c  – 0.070 0.499
 
a
 Correlation is signifi cant at the 0.05 level (2-tailed),  b correlation is signifi cant at the 0.01 level (2-tailed),  c log transformed data. All serum 
(Hcy, folate and B12) correlations were not signifi cant. 
CSF Hcy (data not shown). Figure  2 demonstrates the mul-
tiple adjusted impact of plasma Hcy, CSF 5-methylTHF and 
CSF SAH, on CSF Hcy. 
 Determinants of CSF SAM, SAH and SAM/SAH 
 As shown in Table  3 , CSF SAM showed no signifi cant cor-
relation with any of the potential determinants studied. CSF 
SAH was independently positively correlated with age and 
CSF Hcy, and negatively correlated with CSF 5-methylTHF 
(Figure 2). The CSF SAM/SAH ratio was independently posi-
tively correlated with CSF 5-methylTHF and negatively cor-
related with age and CSF Hcy. None of the serum parameters 
(Hcy, folate and B12) showed any signifi cant correlation with 
CSF SAM, SAH or the SAM/SAH ratio (data not shown). 
 Determinants of CSF 5-methylTHF 
 As shown in Table  4 , CSF 5-methylTHF is negatively correlated 
with age and positively correlated with serum folate concentra-
tions. A multivariate regression model for both age and serum 
folate was applied, showing that both parameters independently 
infl uence CSF 5-methylTHF (Figure 2). Additionally, the ratio 
CSF 5-methylTHF/serum folate was negatively correlated with 
age ( R 2 = 0.076,  ß = – 0.276, p = 0.008). 
 Discussion 
 These are the salient fi ndings of our study in healthy indi-
viduals. Firstly, older age and lower serum folate status are 
independently associated with lower CSF 5-methylTHF 
availability. This may be unfavorable, as we also observed 
that a low CSF folate status adversely affects CSF Hcy and 
methylation potential, at least insofar as the latter is refl ected 
by concentrations of SAH. Secondly, aging also appears to 
directly adversely affect methylation potential, independent 
of CSF folate status. Finally, CSF Hcy appears to be at least 
partly determined by plasma Hcy, suggesting a degree of 
blood-brain equilibration. In the highest tertile of CSF Hcy, 
the contribution of plasma Hcy is less, suggesting that higher 
CSF Hcy is predominantly related to intracerebral metabo-
lism, rather than to equilibration with plasma Hcy. CSF Hcy 
is independently correlated to the concentration of the trans-
methylation inhibitor SAH, which may represent a mecha-
nism of untoward effects of CSF Hcy. 
 The fate of Hcy in CSF will depend on many different 
factors (remethylation, export from brain tissue, trans-
port across the blood-brain barrier, equilibrium with SAH, 
etc). From the perspective of Hcy metabolism (Figure 1), 
the positive correlation of CSF Hcy with both plasma Hcy 
and CSF SAH, and the negative correlation with CSF 5-
methylTHF seem logical  (9) . However, given the strong 
degree of inter-relatedness of 1C metabolites, analyzing sta-
tistical independency of these associations, as we did in the 
current study, is crucial. 
 The methylation potential of cells is conceivably refl ected 
by SAM and SAH (and their ratio), as SAM is a universal 
methyl donor and SAH is an inhibitor of most transmethyla-
tion reactions. However, in line with previously reported data, 
CSF SAM levels did not correlate with any of the other stud-
ied potential determinants  (9) . From a teleological perspec-
tive, this could mean that keeping CSF SAM levels stable is 
vitally important, which would be in keeping with its central 
role not only as a methyl donor, but also as a regulator of 
enzyme activity in both the remethylation and transsulfuration 
pathway. The fact that signifi cantly lower amounts of SAM 
were measured in CSF of patients suffering from depression 
and dementia, may offer insight into how disturbances in 1C 
metabolism and this type of diseases are linked  (10) . It may be 
that intracellular concentrations in brain tissue obtained from 
specifi c regions will offer more insight into these matters, 
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as CSF SAM does not correlate well with intracellular SAM 
concentrations in brain  (28, 29). 
 Levels of the methyltransferase inhibitor SAH were 
adversely associated with higher age and CSF Hcy  (9) . Age 
seems to be a strong determinant of the methylation potential 
in the brain. The underlying mechanism remains unclear. 
 In our study, CSF folate levels were approximately fi ve 
times higher than serum folate levels. Another study  (18) 
showed similar results, while a further one  (9) observed 
higher folate serum levels than in our population and lower 
CSF levels. However, this last study did not use multi vitamin 
intake as an exclusion criteria. This may account for the 
higher plasma values. Perhaps folate demand in the brain is 
higher than in other organs, but exactly how the brain main-
tains its high folate status is mechanistically unknown. The 
relation between increased age and diminished serum folate 
levels has been well documented  (14) . This correlation has 
been attributed to the decreased ability for folate uptake in the 
elderly population  (13, 14) . Our study also showed that age 
was an independent determinant of CSF folate levels, a fact 
that has not been described before to our knowledge. 
 As CSF folate levels have been shown not to follow serum 
folate levels outside the normal range ( ≥ 45 nmol/L)  (9) , 
an additional determinant of CSF folate is of importance. 
Choroid plexus epithelial cells express high levels of folate 
receptor  α , suggesting that a role for it in folate traffi cking 
 (30) . Perhaps transport of folate over the blood-brain bar-
rier is also a determinant of CSF folate and might be the rate 
limiting step. The observation that the CSF/serum folate ratio 
diminishes with age may suggest that this transport alters with 
age. Supplementation might increase the often reduced plasma 
folate levels of the elderly. However, whether this supplemen-
tation will lead to desired increase in CSF folate has yet to be 
determined. Additionally, this observation of hindered trans-
port of folate across the blood-brain barrier could provide 
insight to the origin of the low CSF folate levels observed 
in cerebral folate defi ciency, a treatable neurological abnor-
mality with genetic, acquired or even unknown etiology  (31) . 
Whether defi cient CSF folate refl ects an intracellular folate 
defi ciency in the brain is not well understood. Because of 
the strong observed correlation between CSF folate and CSF 
Hcy, CSF Hcy could be considered to be a more practical bio-
marker (compound stability) of cerebral folate defi ciency. 
 Obtaining CSF samples from healthy volunteers is diffi -
cult. Even though individuals taking medication or suffering 
 Table 4  Univariate and multivariate regression models of 
determinants of CSF 5-methylTHF. 
Regression 
type
Dependent Independent  β p-Value
Univariate CSF 5-methylTHF Age  – 0.242 0.016 a 
Univariate CSF 5-methylTHF Serum folate c   0.504 0.000 b 
Multivariate CSF 5-methylTHF Age  – 0.256 0.004 b 
Serum folate c   0.511 0.000 b 
 
a
 Correlation is signifi cant at the 0.05 level (2-tailed),  b correlation is 
signifi cant at the 0.01 level (2-tailed),  c log transformed data. 
from diseases known to infl uence the 1C metabolism were 
omitted, a certain degree of bias cannot be excluded. 
 Having identifi ed the determinants of 1C metabolites in 
CSF, it will be interesting to investigate whether the same 
determinants play a role in various neurodegenerative diseases 
and whether various intervention strategies can alter CSF 
concentrations of the relevant 1C metabolites, offering path-
ways to prevention and/or treatment. 
 In conclusion, CSF 5-methylTHF levels decrease while 
CSF SAH levels increase with age, which may contribute to 
CNS ageing and neurodegeneration. Higher serum folate con-
centrations were associated with higher CSF concentrations of 
5-methylTHF and with lower levels of the neurotoxic agents 
Hcy and SAH, arguing that folate defi ciency may accelerate 
ageing and neurodegeneration. 
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